RESUMO
BACKGROUND: Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of two new potassium binders (patiromer and sodium zirconium cyclosilicate) led to their recent approval. A major hurdle to the implementation of these potassium-binders is understanding how to integrate them safely and effectively into the long-term management of cardiovascular and kidney disease patients using renin angiotensin aldosterone system inhibitors (RAASi), the latter being prone to induce hyperkalaemia. METHODS: A multidisciplinary academic panel including nephrologists and cardiologists was convened to develop consensus therapeutic algorithm(s) aimed at optimizing the use of the two novel potassium binders (patiromer and sodium zirconium cyclosilicate) in stable adults who require treatment with RAASi and experience(d) hyperkalaemia in a non-emergent setting. RESULTS: Two dedicated pragmatic algorithms are proposed. The lowest intervention threshold (i.e. 5.1â¯mmol/L or greater) was the one used in the patiromer and sodium zirconium cyclosilicate) pivotal trials, both drugs being indicated to treat hyperkalaemia in a non -emergent setting. Acknowledging the heterogeneity across specialty guidelines in hyperkalaemia definition and thresholds to intervene when facing hyperkalaemia, we have been mindful to use soft language i.e. "it is to consider", not necessarily "to do". CONCLUSIONS: Providing the clinical community with pragmatic algorithms may help optimize the management of high-risk patients by avoiding the risks of both hyper and hypokalaemia and of suboptimal RAASi therapy.
Assuntos
Cardiopatias , Insuficiência Cardíaca , Hiperpotassemia , Insuficiência Renal Crônica , Adulto , Algoritmos , Humanos , Hiperpotassemia/diagnóstico , Hiperpotassemia/tratamento farmacológico , Hipertensão Renal , Nefrite , Potássio , Insuficiência Renal Crônica/tratamento farmacológico , Sistema Renina-AngiotensinaRESUMO
BACKGROUND: Transplant kidney biopsies are performed to determine a histological diagnosis for specific patient treatment. The aim of this study was to investigate if Resistive Index (RI) could be a predictor for biopsy complications. METHODS: In this study, 220 consecutive transplant kidney biopsies (136 men and 84 women; median age, 55.5 years) were prospectively included. RI (median, 0.7) was measured by use of ultrasound. Histological diagnoses and biopsy complications were registered. Biopsy needles were either 16- or 18-gauge. Biopsies were performed by radiologists and were carried out as an outpatient procedure (70%) or an inpatient procedure (30%). Usually three passes per biopsy were performed. RESULTS: The overall complication rate was 6.8%, divided into major (4.5%) and minor (2.3%) complications. An RI ≥0.8 predicts major (13.3% versus 3.2%; risk ratio [RR], 4.2; confidence interval [CI], 1.3-14.1; P = .03) and overall biopsy complications (16.7% versus 5.3%; RR, 3.2; CI, 1.2-8.6; P = .04) compared with RI <0.8. In the group <0.8, RI correlated with age (rs = 0.28, P < .001) and systolic blood pressure (rs = 0.18, P = .02). In the group ≥0.8, RI correlated with degree of interstitial fibrosis (rs = 0.65, P = .006) and systolic blood pressure (rs = 0.40, P = .03). The multiple regression analysis showed that in the group <0.8, the RI correlated only with age (P < .001), whereas in the group ≥0.8, RI correlated only with the degree of interstitial fibrosis (P = .003). CONCLUSIONS: An RI ≥0.8 indicates greater risk for major and overall biopsy complications and should result in greater caution after biopsy.
Assuntos
Biópsia por Agulha/efeitos adversos , Transplante de Rim , Rim/cirurgia , Complicações Pós-Operatórias , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , RiscoRESUMO
Inflammatory pseudotumour is a rare condition that can affect various organs. The clinical and histologic appearance of the pseudotumour may mimic haematological, lymphoproliferative, paraneoplastic or malignant processes. A previously healthy 39-year-old man presented with nephrotic syndrome. He had a history of headaches, nausea and swollen ankles. Computed tomography of the abdomen revealed a 6-cm mass in the spleen. Following a renal biopsy, a diagnosis of membranoproliferative glomerulonephritis (MPGN) type I was made. Splenectomy was performed and the examination revealed a mixed population of lymphocytes with predominantly T-cells, B-cells and lymphoplasmacytoid cells. Immunostaining confirmed that the small cells were mostly T-cells positive for all T-cell markers including CD2, CD3, CD4, CD5, CD7 and CD8. A diagnosis of inflammatory pseudotumour was established. The removal of the spleen was followed by remission of glomerulonephritis, but it was complicated by a subphrenic abscess and pneumonia. This association between an inflammatory pseudotumour of the spleen and MPGN has not been previously described. Abnormal immune response due to the inflammation leading to secondary glomerulonephritis might be the main pathogenic mechanism.
RESUMO
This report described an interim analysis of a investigator-driven multicenter trial in renal transplant recipients: the Prospective Quality of life Renal Transplantation Switch Study; Tacrolimus-based immunosuppression ("PQRST study"). Patients included in the trial initially treated with cyclosporine-based immunosuppression after renal transplantation who experienced side effects, such as hypertension, hyperlipidemia, hypertrichosis, or other adverse reactions, were converted to a tacrolimus-based immunosuppressive regimen (n = 31). Steroids were subsequently discontinued between 3 and 6 months after the conversion. As of today 19/31 (50%) patients have been successfully weaned off steroids with the remaining patients in this process. In this interim analysis, with a follow-up ranging from 1 to 18 months both patient and graft survivals were 100%. No patient experienced an acute rejection episode; none of the grafts were lost. Blood pressure decreased in 22/31 (71%) of the patients. No patient developed de novo diabetes or other serious side effect related to the conversion. Three patients were withdrawn from the trial because of side effects: bleeding, depression, and proteinuria. However, none of these adverse events were felt to be directly related to the change of the immunosuppressive regimen to tacrolimus monotherapy. In conclusion, conversion from cyclosporine to tacrolimus-based therapy was safe and well tolerated; it may improve the cardiovascular risk profile after kidney transplantation.
Assuntos
Transplante de Rim/fisiologia , Tacrolimo/uso terapêutico , Adulto , Idoso , Creatinina/sangue , Ciclosporina/uso terapêutico , Feminino , Seguimentos , Sobrevivência de Enxerto , Humanos , Imunossupressores/uso terapêutico , Nefropatias/classificação , Nefropatias/cirurgia , Transplante de Rim/imunologia , Masculino , Pessoa de Meia-Idade , Transplante HomólogoRESUMO
UNLABELLED: The risk of death is higher in dialysis patients compared to age matched healthy subjects, the main reason being cardiovascular. This prospective study investigated if the extent of ultrafiltration was of importance for the outcome. MATERIAL AND METHODS: 88 hemodialysis patients were included and followed prospectively. The outcome was registered in regard to death, acute myocardial infarction or coronary vascular intervention. The extent of ultrafiltration needed at dialysis was calculated as a mean during the observation period as were other variables. The mean extent of ultrafiltration was compared for patients who had survived without end-points (group 1, n=53) versus those who reached any end-point during the period (group 2, n=35). RESULTS: In total, 40% of the patients reached end-point during the observation period. There was no difference at baseline between the groups in regard to age, prevalence of diabetes mellitus or history of previous cardiovascular disease, KT/V, residual renal function ultrafiltration need, C-reactive protein, s-albumin, cholesterol, LDL-cholesterol, HDL-cholesterol, appetite or wellbeing, while triglyceride was lower in group 2 (p=0.035). The observation period for group 1 was at a mean 24.7 months (SD13.1) and for those in group 2 at a mean 13.8 (+/-11.7 months, p<0.001). Patients representing group 1 at 24 and 30 months had less need of ultrafiltration than those in group 2. Thus, the need of ultrafiltration was about 27% lower at 24 months (for 29 persons in group 1: 3.63+/-1.93 weight% versus 4.97+/-1.70 weight% for 9 patients from group 2, p=0.046) and 46% at 30 months (for 18 from group 1: 3.48+/-1.95 versus 6.45+/-1.55 for 3 from group 2, p=0.030). C-reactive protein did not differ significantly between the groups during the period. CONCLUSION: After a prolonged period of 24 months the extent of ultrafiltration need seems to be important for the outcome of the patients. Thereby those with higher need of ultrafiltration had worse prognosis. It seems important to motivate patients to reduce the extent of fluid intake between dialysis to prolong survival.
Assuntos
Hemodiafiltração , Insuficiência Renal/mortalidade , Aumento de Peso , Adulto , Idoso , Idoso de 80 Anos ou mais , Proteína C-Reativa/análise , Humanos , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Estudos Prospectivos , Insuficiência Renal/terapiaRESUMO
OBJECTIVE: To investigate the efficacy and safety of a daily dose of 10 mg of atorvastatin in patients with chronic kidney disease (CKD) stages 4 and 5 and a glomerular filtration rate of <30 ml/min. MATERIAL AND METHODS: This was an open, prospective, randomized study. A total of 143 patients were included: 73 were controls and 70 were prescribed 10 mg/day of atorvastatin. As efficacy variables, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels were determined at the start of the study and at 1, 3, 6, 12, 18, 24, 30 and 36 months. RESULTS: The follow-up period was a mean of 20+/-14.4 months (range 1-36 months) for those on atorvastatin versus 22+/-12.7 months (range 0.5-36 months) for the controls. Compared with baseline values, patients treated with atorvastatin had significantly lower concentrations of total cholesterol at Month 36 (5.8 vs 4.4 mmol/l; -23%; p<0.001), of LDL cholesterol at Month 36 (3.6 vs 2.2 mmol/l; -35%; p<0.001) and of triglycerides at Months 24 (2.5 vs 1.9 mmol/l) and 36 (2.5 vs 1.8 mmol/l). The controls had significantly reduced levels of total cholesterol at Month 36 (p<0.21) and of LDL cholesterol at Months 30 and 36. Compared with the controls, the atorvastatin group had lower levels of total cholesterol and LDL cholesterol at Months 1-30. Fifteen patients (21%) stopped taking their medication as they could not tolerate the side-effects, the most frequent complaints being gastrointestinal discomfort and headache. CONCLUSION: Although the medication caused no severe adverse events, we recommend caution when using atorvastatin for severe CKD patients until further evidence of its safety and efficacy is verified.
Assuntos
Anticolesterolemiantes/uso terapêutico , Ácidos Heptanoicos/uso terapêutico , Falência Renal Crônica/tratamento farmacológico , Pirróis/uso terapêutico , Idoso , Anticolesterolemiantes/efeitos adversos , Atorvastatina , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , HDL-Colesterol/sangue , HDL-Colesterol/efeitos dos fármacos , LDL-Colesterol/sangue , LDL-Colesterol/efeitos dos fármacos , Feminino , Seguimentos , Taxa de Filtração Glomerular , Ácidos Heptanoicos/efeitos adversos , Humanos , Falência Renal Crônica/sangue , Falência Renal Crônica/complicações , Masculino , Estudos Prospectivos , Pirróis/efeitos adversos , Índice de Gravidade de Doença , Resultado do Tratamento , Triglicerídeos/sangueRESUMO
OBJECTIVE: There have been no endpoint studies with statins for patients with severe renal failure. The purpose of this prospective, open, randomized, controlled study was to investigate whether atorvastatin (10 mg/day) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 (creatinine clearance < 30 ml/min). MATERIAL AND METHODS: The study subjects comprised 143 patients who were randomized either to placebo (controls; n=73; mean age 69.5 years) or to treatment with atorvastatin (n=70; mean age 67.9 years). The patients included were either non-dialysis (n=33), haemodialysis (n=97) or peritoneal dialysis (n=13) patients. Analysis focused on the primary endpoints of all-cause mortality, non-lethal acute myocardial infarction, coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Statistical analysis for endpoint data was mainly by intention-to-treat. RESULTS: Primary endpoints occurred in 74% of the subjects. There was no difference in outcome between the control and atorvastatin groups. The 5-year endpoint-free survival rate from study entry was 20%. Atorvastatin was withdrawn in 20% of patients due to unacceptable side-effects. In the atorvastatin group, low-density lipoprotein (LDL) cholesterol was reduced by 35% at 1 month and then sustained. The controls showed a progressive reduction in LDL cholesterol until 36 months. CONCLUSIONS: Although atorvastatin reduced total and LDL cholesterol effectively it was not beneficial regarding the long-term outcomes of cardiovascular endpoints or survival. In contrast to other patient groups, patients with severe chronic kidney disease, especially those on dialysis, seem to derive limited benefit from this lower dose of atorvastatin.
Assuntos
Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Ácidos Heptanoicos/administração & dosagem , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Falência Renal Crônica/mortalidade , Pirróis/administração & dosagem , Idoso , Angioplastia Coronária com Balão , Atorvastatina , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/terapia , Ponte de Artéria Coronária , Relação Dose-Resposta a Droga , Feminino , Humanos , Falência Renal Crônica/complicações , Masculino , Infarto do Miocárdio/etiologia , Infarto do Miocárdio/prevenção & controle , Infarto do Miocárdio/terapia , Estudos ProspectivosRESUMO
BACKGROUND/AIM: Aneurysms are known manifestations of autosomal dominant polycystic kidney disease (ADPKD). We investigated whether the dimensions of arteriovenous fistulas created for performance of haemodialysis were affected by the original disease. METHODS: The lumen diameter of the fistula was studied by ultrasound in 19 patients with ADPKD and in 19 control patients. The patients' sex, age, the duration of their fistulas, haemoglobin values and blood pressure levels were similar in both groups. The monitoring was performed along the forearm part of the vein, and the maximal diameter was measured. The diameters at the two needle insertion sites were also measured. RESULTS: The ADPKD patients had a significantly higher fistula diameter than the control patients: 12 (range 8-19) mm versus 8 (range 6-24) mm at the widest level (p = 0. 003). There were no significant differences in the diameters at the needle insertion sites. CONCLUSION: The receiving veins of arteriovenous fistulas in patients with ADPKD have an abnormality that causes a greater than normal dilatation in response to the arterialization. We postulate that this phenomenon is linked with the increased prevalence of aneurysms in ADPKD.
Assuntos
Aneurisma/epidemiologia , Derivação Arteriovenosa Cirúrgica , Rim Policístico Autossômico Dominante/epidemiologia , Rim Policístico Autossômico Dominante/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Aneurisma/patologia , Artérias/patologia , Feminino , Humanos , Masculino , Agulhas , Prevalência , Diálise Renal , Falha de Tratamento , Veias/patologiaRESUMO
Patients with autosomal dominant polycystic kidney disease (ADPKD) have an increased risk of intracranial aneurysms. Reports on arterial aneurysms in other locations have not been conclusive. The present study was initiated to investigate the prevalence of coronary aneurysms. Thirty ADPKD patients who had undergone coronary angiography on clinical indication were identified, 15 after renal transplantation. For each ADPKD patient, a control patient was identified with end-stage renal disease, investigated by coronary angiography, and matched for age, sex, and time relation to transplantation. All angiograms were retrieved and reevaluated with respect to aneurysms, defined as an increase in artery diameter by 50% or more, as well as to pathologic ectasias not fulfilling this criterion. Aneurysms were detected in four ADPKD patients and two control subjects. Five more ADPKD patients, but none of the control subjects, had minor ectasias. One ADPKD patient had a dissecting aortic aneurysm, and another died of aortic dissection during bypass surgery. This study adds to the evidence of an increased risk of extracranial aneurysms in ADPKD patients.
Assuntos
Aneurisma Coronário/complicações , Rim Policístico Autossômico Dominante/complicações , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/mortalidade , Aneurisma Coronário/diagnóstico por imagem , Aneurisma Coronário/epidemiologia , Angiografia Coronária , Humanos , Rim Policístico Autossômico Dominante/diagnóstico por imagem , PrevalênciaRESUMO
OBJECTIVE: To investigate whether there are specific complications to continuous ambulatory peritoneal dialysis (CAPD) in patients with autosomal dominant polycystic kidney disease (ADPKD) due to defects in various wall structures--causing hernia and diverticulitis--and to enlarged kidneys. DESIGN: The clinical experience of CAPD in 26 patients with ADPKD, treated for 11+/-6 months, was studied in retrospect and compared with that of 26 contemporary controls. Medical records were reviewed with respect to survival in this treatment form and any complication. Peritoneal dialysis capacity (PDC), as measured in 21 ADPKD patients and 20 controls, was also evaluated. SETTING: University Hospital. RESULTS: Before initiation of CAPD, enlarged kidneys necessitated nephrectomy in 2 of 26 ADPKD patients; both cases were registered as preparation for transplantation, not for CAPD. Survival in CAPD was similar in ADPKD patients and controls. Hernia was present in 4 ADPKD patients and 2 controls, and required transfer to hemodialysis in 1 patient from each group, temporarily. The incidence of peritonitis was 1 per 20 months in ADPKD patients versus 1 in 27 months in the controls, not significantly different. Peritonitis was caused by colonic bacteria in similar numbers. Residual renal function was 1.9 2.1 mL/min per 1.73 m2 in ADPKD patients versus 1.9+/-1.4 mL/min per 1.73 m2 in the controls. No difference was detected in any of the variables measured by PDC. CONCLUSION: There were no specific problems related to ADPKD.
Assuntos
Diálise Peritoneal Ambulatorial Contínua , Rim Policístico Autossômico Dominante/terapia , Análise Atuarial , Índice de Massa Corporal , Peso Corporal , Colo/microbiologia , Doença Diverticular do Colo/etiologia , Infecções por Escherichia coli , Feminino , Seguimentos , Hérnia Ventral/etiologia , Humanos , Incidência , Infecções por Klebsiella , Masculino , Pessoa de Meia-Idade , Nefrectomia , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Diálise Peritoneal Ambulatorial Contínua/métodos , Peritonite/etiologia , Peritonite/microbiologia , Rim Policístico Autossômico Dominante/fisiopatologia , Rim Policístico Autossômico Dominante/cirurgia , Infecções por Pseudomonas , Diálise Renal , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do TratamentoRESUMO
Allergic nephropathy associated with quinolone antibiotics has been reported in an increasing number of cases. The mechanism might be a hypersensitivity reaction. Norfloxacin has been incriminated previously as a cause once only, with acute interstitial nephritis (AIN) as the histopathological finding. Ciprofloxacin-associated nephropathy has been reported in 28 cases, with AIN as the main histopathological finding. This report describes a second case of AIN associated with norfloxacin treatment and another ciprofloxacin-associated renal interstitial drug adverse reaction. Clinicians should be aware of quinolone-associated AIN, which is a rare but potentially dangerous renal complication.
Assuntos
Anti-Infecciosos/efeitos adversos , Ciprofloxacina/efeitos adversos , Hipersensibilidade a Drogas/etiologia , Nefrite Intersticial/induzido quimicamente , Norfloxacino/efeitos adversos , Idoso , Anti-Infecciosos/uso terapêutico , Biópsia , Ciprofloxacina/uso terapêutico , Hipersensibilidade a Drogas/diagnóstico , Hipersensibilidade a Drogas/epidemiologia , Feminino , Humanos , Rim/patologia , Nefrite Intersticial/diagnóstico , Nefrite Intersticial/epidemiologia , Norfloxacino/uso terapêuticoRESUMO
AIM: To define specific manifestations of autosomal dominant polycystic kidney disease in kidney transplant patients. METHODS: Of 874 consecutive first renal transplant patients 1985-1993, 114 (13%) had autosomal dominant polycystic kidney disease (ADPKD). Mean age was 53 +/- 8 years, 62% were men, and 83% received cadaveric kidneys. Control patients were matched for sex, age and donor type. Median follow-up time was 63 months. One patient was lost to follow-up. Medical records before and after transplantation were reviewed. RESULTS: Survival of patients and grafts was similar in ADPKD patients and controls. Twenty-five ADPKD patients died, four of causes not seen in the controls; two aortic aneurysms, one urothelial cancer, one colon perforation. Four more ADPKD patients but no control had diverticulitis (P = 0.03), two with perforation. Cardiovascular morbidity was not increased. Eight patients had subarachnoidal haemorrhage before transplantation and two during follow-up. Nineteen patients had undergone nephrectomy before transplantation, 11 because of voluminous kidneys, five for infection, pain or bleeding, two for suspected malignancy, one for hypertension. After transplantation, seven patients underwent nephrectomy, only one related to kidney size. During the first year, need of phlebotomy occurred in 14% of patients versus 4% of controls, P = 0.02. Urinary tract infection rates were not increased. No morbidity was related to liver cysts. CONCLUSION: The specific features of kidney transplantation to patients with ADPKD were few: enlarged kidneys, relevant only before transplantation, erythrocytosis, and as rare but serious events, diverticulitis with perforation.
Assuntos
Transplante de Rim , Rim Policístico Autossômico Dominante/complicações , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
In a prospective study before, and during 1 year following, kidney transplantation, physical strength and performance were tested in patients over the age of 60 and in younger control patients. Quadriceps strength increased significantly in the control patients (+3.3 +/- 3.2 kg, n = 11, P = 0.007) but remained stable in the successfully grafted elderly patients (-0.1 +/- 4.2 kg, n = 16). Grip strength tended to increase in the control patients (P = 0.064) but not in the elderly. Stepping up on a chair--a test of strength and coordination in combination--could be performed by all control patients on all occasions. Fourteen of 16 elderly patients managed it before transplant, but only 3/12 after 3 weeks, 5/13 after 6 months, and 10/16 after 1 year. Forced expiratory volume during 1 s and working capacity on the ergometer bicycle also tended to decline during 1 year. We conclude that the average elderly person does not gain strength during 1 year after successful kidney transplantation.
Assuntos
Exercício Físico/fisiologia , Transplante de Rim/fisiologia , Músculo Esquelético/fisiologia , Adolescente , Adulto , Fatores Etários , Idoso , Teste de Esforço , Feminino , Humanos , Nefropatias/cirurgia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Testes de Função RespiratóriaRESUMO
Inflammatory pseudotumours are rare benign pulmonary lesions varying in localization, size and clinical features, and can pose difficulties with differential diagnosis. The radiological appearance is unspecific and the histopathological picture polymorphous. The aetiology is unknown. A case of intrathoracic plasma cell granuloma is reported.